18 Results for "

PD-L1-IN-3

" in MedChemExpress (MCE) Product Catalog:
Products (18)

18 Results for "PD-L1-IN-3" in MCE Product Catalog:

Cat. No.: HY-155101
CAS No.: 2953044-29-4
Purity:  99.52%
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC50 value and EC50 value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-75502
CAS No.: 99755-59-6
Synonyms: N-0923; (-)-N 0437
Rotigotine is a potent dopamine receptor agonist with Ki values of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-110125
CAS No.: 713121-80-3
Purity:  99.82%
Synonyms: CID 1261822
Target:  

GPR55

Research Areas:  

Neurological Disease

ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC50 of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats .
loading...
    loading...
Cat. No.: HY-103048A
Purity:  99.34%
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .
loading...
    loading...
Cat. No.: HY-103048
CAS No.: 1629654-95-0
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .
loading...
    loading...
Cat. No.: HY-145240
CAS No.: 2573979-31-2
Research Areas:  

Infection Cancer

eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y) .
loading...
    loading...
Cat. No.: HY-P990698
CAS No.: 2599198-83-9

Target:  

PD-1/PD-L1 EGFR

Research Areas:  

Inflammation/Immunology

Umizortamig is an anti-CD3E/EGFR/TNFRSF9/PD-L1/CD3G monoclonal antibody .
loading...
    loading...
Cat. No.: HY-177801
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

XQ-P3 sodium is an aptamer that binds to PD-L1. XQ-P3 can inhibit the PD-1/PD-L1 interaction and restore the function of T cells to detect and attack tumor cells.
loading...
    loading...
Cat. No.: HY-156151
CAS No.: 3032386-59-4
Research Areas:  

Infection

CYP51/PD-L1-IN-3 (compound L21) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-3 is a dual inhibitor of CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-3 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
loading...
    loading...
Cat. No.: HY-173558
Target:  

PD-1/PD-L1 HDAC Apoptosis

Research Areas:  

Cancer

PD-L1/HDAC3-IN-1 (PH3) is a dual PD-L1/HDAC3 Inhibitor with IC50 values of 89.4 nM and 107 nM for PD-1/PD-L1 and HDAC3, respectively. PD-L1/HDAC3-IN-1 induces cell apoptosis and arrests cell cycle at G0/G1 phase. PD-L1/HDAC3-IN-1 shows anticancer activity both in vivo and in vitro .
loading...
    loading...
Cat. No.: HY-169365
CAS No.: 2766689-18-1
Target:  

PD-1/PD-L1

Research Areas:  

Others

2-Methylbiphenyl-oxadiazole-NH-Ph-CHO is the PD-L1 ligand part of AUTAC PD-L1 degrader-3 (HY-169363). 2-Methylbiphenyl-oxadiazole-NH-Ph-CHO can be utilized in AUTAC synthesis .
loading...
    loading...
Cat. No.: HY-172133
CAS No.: 3070532-72-5
HDAC3-IN-6 (Compound SC26) is a selective HDAC3 inhibitor with an IC50 of 53 nM. HDAC3-IN-6 dose-dependently induces the expression of PD-L1. HDAC3-IN-6 induces more pronounced Apoptosis and production of ROS. HDAC3-IN-6 exhibits high antitumor efficacy against colorectal cancer .
loading...
    loading...
Cat. No.: HY-169364
Target:  

PD-1/PD-L1

Research Areas:  

Others

2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc is the PD-L1 ligand-linker conjugate part of AUTAC PD-L1 degrader-3 (HY-169363). 2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc can be utilized in AUTAC synthesis .
loading...
    loading...
Cat. No.: HY-75502R
CAS No.: 99755-59-6
Synonyms: N-0923 (Standard); (-)-N 0437 (Standard)
Rotigotine (Standard) is the analytical standard of Rotigotine. This product is intended for research and analytical applications. Rotigotine is a potent dopamine receptor agonist with Ki values of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research .
loading...
    loading...
Cat. No.: HY-182982
CAS No.: 1251828-93-9
Target:  

PROTAC Linkers

Research Areas:  

Cancer

7-[(2-Aminoethyl)carbamoyl]heptanoic acid is a PROTAC linker that can be used to synthesize PROTAC molecules, such as PROTAC PD-L1 Degrader-3 (HY-182959) .
loading...
    loading...
Cat. No.: HY-182980
N-(8-Carboxyoctanoyl)-deacetyl BMS-202 is a target protein ligand-linker conjugate. N-(8-Carboxyoctanoyl)-deacetyl BMS-202 contains the target protein PD-1/PD-L1 ligand and a PROTAC linker. N-(8-Carboxyoctanoyl)-deacetyl BMS-202 can be used for the synthesis of PROTAC PD-L1 Degrader-3 (HY-182959) .
loading...
    loading...
Cat. No.: HY-110125R
CAS No.: 713121-80-3
Synonyms: CID 1261822 (Standard)
Research Areas:  

Neurological Disease

ML-193 (Standard) is the analytical standard of ML-193 (HY-110125). This product is intended for research and analytical applications. ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC50 of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of ParKinson’s disease (PD) rats .
loading...
    loading...
Cat. No.: HY-183607
Research Areas:  

Cancer

SMU-3k is a STING activator and PD-L1 inhibitor, with a PD-L1 IC50 of 106 nM, a KD of 386 nM for human PD-L1, and a KD of 352 nM for murine PD-L1. SMU-3k activates the STING pathway, induces phosphorylation of TBK1 and IRF3, and promotes the expression of IFN-β, IL-6 and CXCL10. SMU-3k blocks the PD-1/PD-L1 interaction, reduces PD-L1 levels and induces PD-L1 internalization. Through dual immunomodulation, SMU-3k exerts synergistic tumor growth inhibitory effects in a mouse colon cancer model. SMU-3k can be used for the research of colon cancer .
loading...
    loading...
  • 1